News

Citi Raises PT on Pfizer Inc. (PFE) to $26; Maintains ‘Neutral’ Rating

With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the ...

Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial

Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now. On August 12, 2025, ...
Medical Dialogues8h

Padcev plus Keytruda significantly improves survival for certain patients with bladder cancer when given before, after surgery: Pfizer

Pfizer Inc. and Astellas Pharma Inc. have announced positive topline results from the Phase 3 EV-303 clinical trial (also ...